SKIN OINTMENT FOR TREATING LABIA MINORA SKIN

Abstract

According to a skin ointment for treating labia minora skin according to the present disclosure, the skin ointment includes multi-growth factors as active ingredients, and is periodically applied to the vulva of a user so that the growth factors induce the regeneration of skin cells of the user, thereby increasing the effect of treating vulvar vestibulitis or wounds due to labia minora surgery, and addressing the fundamental causes thereof.

Claims

1. A skin ointment for treating labia minora skin, the skin ointment comprising multi-growth factors as active ingredients, wherein the multi-growth factors are multi-growth factors comprising FGF, bFGF, GM-CSF, HGF, IGF-1, IL-6,7,8, KGF, Matrix proteins, PDGF-AA, TGF-B2, TGF-B3, EGF, VEGF, and TNF, and the skin ointment treating wounds due to labia minora surgery, and being in an ointment formulation, the ointment formulation being a semi-solid drug for external use.

2. The skin ointment of claim 1, wherein the skin ointment is periodically applied to a vulva of a user to treat vulvar vestibulitis.

3. A skin ointment for treating labia minora skin, the skin ointment comprising multi-growth factors as active ingredients, wherein the multi-growth factors are multi-growth factors comprising FGF, bFGF, GM-CSF, HGF, IGF-1, IL-6,7,8, KGF, Matrix proteins, PDGF-AA, TGF-B2, TGF-B3, EGF, VEGF, and TNF, and the skin ointment comprising, conditioned medium of growth factor containing the multi-growth factors with on a weight basis, 20%-40% of a high-concentration, and being in an ointment formulation, the ointment formulation being a semi-solid drug for external use.

4. The skin ointment of claim 3, wherein the high-concentration growth factor conditioned medium is included at a concentration of 300,000 ppm on a weight basis.

5. The skin ointment of claim 3, wherein the skin ointment is prepared as an ointment formulation comprising purified water, glycerin, Simmondsia chinensis (jojoba) seed oil, xanthan gum, a hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, squalane, polysorbate 60, Rosmarinus officinalis (rosemary) leaf oil, lactic acid, chlorphenesin, and sorbitan isostearate.

6. The skin ointment of claim 3, wherein the skin ointment excludes female hormones, environmental hormones, steroid hormones, and antibiotic ingredients.

7. The skin ointment of claim 1, wherein the skin ointment is prepared as an ointment formulation comprising purified water, glycerin, Simmondsia chinensis (jojoba) seed oil, xanthan gum, a hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, squalane, polysorbate 60, Rosmarinus officinalis (rosemary) leaf oil, lactic acid, chlorphenesin, and sorbitan isostearate.

8. The skin ointment of claim 1, wherein the skin ointment excludes female hormones, environmental hormones, steroid hormones, and antibiotic ingredients.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0025] FIG. 1 is a view for explaining the surgical trend of labial hypertrophy.

[0026] FIG. 2 is a view for explaining the efficacy of growth factors.

[0027] FIG. 3 is a view showing the ingredients of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure.

[0028] FIG. 4 shows images showing an observed state of the degree of recovery through application of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure to patients who have undergone labia minora surgery and clitoroplasty.

[0029] FIG. 5 shows images showing an observed state of the degree of recovery through application of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure to patients who have undergone surgery for labial hypertrophy.

[0030] FIG. 6 shows images showing an observed state of the degree of recovery through application of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure to patients diagnosed with vulvar vestibulitis and atrophic vaginitis.

BEST MODE

[0031] Hereinafter, example embodiments will be described in detail with reference to the accompanying drawings in such a manner that the present disclosure may be easily carried out by one of ordinary skill in the art to which the present disclosure pertains. However, in detailed description of example embodiments of the present disclosure, detailed description of related functions or configurations will be omitted when it is deemed that they may unnecessarily obscure the essence of the present disclosure. In addition, components having similar functions and actions are denoted by like reference numerals throughout the drawings.

[0032] In addition, in the entire specification, when a part is referred to as being connected with another part, it includes not only a case where it is directly connected, but also a case where a part is indirectly connected with another part with another element disposed therebetween. In addition, including an element means that, unless otherwise specifically stated, other elements are not precluded and also may mean that other elements are further included.

[0033] A skin ointment for treating labia minora skin according to an embodiment of the present disclosure includes multi-growth factors as active ingredients. Previously, products used for vaginitis and the like have been used to treat labia minora skin, but the skin ointment for treating labia minora skin according to the present disclosure, which has a function of inducing regeneration by using growth factors, particularly multi-growth factors, has a distinct difference from existing ointment products that do not use growth factors. In particular, the present disclosure is meaningful in that the skin ointment is not a temporary pain relief product, but regenerates skin tissue and a vaginal mucosa layer, which addresses the fundamental causes of symptoms.

[0034] FIG. 2 is a view for explaining the efficacy of growth factors. As illustrated in FIG. 2, growth factors promote the growth, proliferation, and differentiation of cells by binding to the receptors of the cells, thereby enabling the natural regeneration cycle of the skin of a user to smoothly proceed. That is, growth factors are responsible for increasing the amounts of collagen and elastin in the skin and regenerating the skin, and since the labia minora skin of women also consists of collagen, the efficacy of growth factors in facilitating the regeneration cycle of cells may be obtained, and ultimately, fundamental causes may be addressed.

[0035] In the present disclosure, growth factors are absorbed into the labia minora skin of a user to induce the regeneration of skin cells of the user, and may be multi-growth factors including FGF, bGFG, GM-CSF, HGF, IGF-1, IL-6,7,8, KGF, Matrix proteins, PDGF-AA, TGF-B2, TGF-B3, EGF, VEGF, and TNF. In particular, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure does not use EGF or FGF alone as a growth factor, but may contain multi-growth factors as listed above in the form of a multi-peptide factor protein.

[0036] Growth factors have different functions. For example, EGF is an epithelial growth factor that helps the growth of epithelial cells, and FGF is a growth factor that stimulates the production of fibroblasts, has a function of strengthening wound healing ability and promoting skin regeneration, and is involved in skin tissue reconstruction by secreting collagen. In addition, PDGF stimulates angiogenesis, removes wound tissue, and promotes healing, and KGF stimulates the division and differentiation of angiogenic cells, improves the function of monocytes and macrophages, and promotes the proliferation of epidermal cells. Since cells constituting the body do not consist of only single cells, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure includes multi-growth factors, and thus may help the proliferation and regeneration of various cells using various growth factors, thereby obtaining a more rapid regeneration rate and effect.

[0037] For the treatment of labia minora skin, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure including multi-growth factors may be applied to the skin of a corresponding site to enable the multi-growth factors to permeate into the skin of a user, thereby enhancing the effect of ameliorating and treating labia minora skin diseases. Growth factors are advantageous in terms of no immune rejection response and no side effects.

[0038] The skin ointment for treating labia minora skin according to an embodiment of the present disclosure may include multi-growth factors at a concentration of 200,000 ppm to 400,000 ppm on a weight basis, and more particularly, may include the multi-growth factors at a concentration of 300,000 ppm on a weight basis. That is, the multi-growth factors included in the skin ointment for treating labia minora skin according to an embodiment of the present disclosure is in the form of a conditioned medium of growth factor with 20% to 40% high-concentration, preferably a conditioned medium of growth factor with 30% high-concentration. In some embodiments, the conditioned medium of growth factor with 30% high-concentration may be a mixture of natural nutrients and moisturizing ingredients.

[0039] Conventional skin products including growth factors are mostly 1,000 ppm or less, and the concentration is not disclosed separately due to the low concentration. Thus, even a concentration of about 2,000 ppm may be distinguished from conventional skin products. The skin ointment for treating labia minora skin according to an embodiment of the present disclosure includes a high concentration of multi-growth factors of 200,000 ppm to 400,000 ppm, which is 10-20 times that of growth factors included in conventional skin products. Due to such a difference, the effect of the skin ointment on the amelioration and treatment of skin has a significant difference from that of low-concentration products.

[0040] In particular, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure uses growth factor conditioned media to produce growth factors that are most optimized for the skin and tissue of the human body, thereby maximizing the effect of regenerating the skin tissues and cell membranes of the labia minora. In other words, when growth factors in the form of powder obtained by pulverizing a frozen powder form is added during product formulation, it is difficult to accurately specify the content thereof. In addition, since growth factors themselves are proteins, when these are frozen, the effect is remarkably reduced (80-90% or more) as compared to a protein form. In contrast, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure uses growth factor conditioned media that maintain a protein form as it is, and thus, as compared to the case where growth factors in the form of frozen powder are used, a significantly excellent effect may be obtained.

[0041] In addition, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure may exclude female hormones, environmental hormones, steroid hormones, and antibiotic ingredients, and thus can be safely used by pregnant or breast-feeding women. In some embodiments, the skin ointment may further include at least one of vitamins, amino acids, and hyaluronic acid.

[0042] FIG. 3 is a view showing the ingredients of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure. As illustrated in FIG. 3, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure includes 30 wt % of multi-growth factors, and may be prepared as an ointment formulation including purified water, glycerin, Simmondsia chinensis (jojoba) seed oil, xanthan gum, a hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, squalane, polysorbate 60, Rosmarinus officinalis (rosemary) leaf oil, lactic acid, chlorphenesin, and sorbitan isostearate.

[0043] Most of conventional skin products including growth factors are in the form of ampoules or light creams. In particular, when growth factors are contained at a high concentration, it is difficult to prepare an ointment formulation, which is a semi-solid drug for external use. However, since the skin ointment for treating labia minora skin according to an embodiment of the present disclosure includes the ingredients as shown in FIG. 3, the skin ointment not only includes a high concentration of multi-growth factors of 300,000 ppm, but is also prepared as an ointment formulation, and thus is different from ampoule or cream types in terms of viscosity and tactility, which facilitates the application thereof to labia minora skin. In particular, it is not easy for a user to directly apply a light product to labia minora skin, and it is difficult for multi-growth factors to be sufficiently absorbed into the vulvar skin due to wearing of underwear, activities, and the like. Thus, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure is prepared as a semi-solid skin ointment formulation including a high concentration of multi-growth factors, and thus is easily applied to labia minora skin and enables the high concentration of multi-growth factors to be sufficiently absorbed into the skin, and accordingly, has a significant effect on the treatment of vulvar vestibulitis or wounds due to labia minora surgery.

EXAMPLE 1

[0044] Among from human fibroblasts (extracted from the foreskin) supplied from Tissue Bank at University of California, Ivine, healthy living fibroblasts were selected and cultured such that a constant growth factor concentration was maintained in all culture processes, thereby producing multi-growth factors in a conditioned media form. The produced multi-growth factors include FGF, bGFG, GM-CSF, HGF, IGF-1, IL-6,7,8, KGF, Matrix proteins, PDGF-AA, TGF-B2, TGF-B3, EGF, VEGF, and TNF. The multi-growth factors were mixed with purified water, glycerin, Simmondsia chinensis (jojoba) seed oil, xanthan gum, a hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, squalane, polysorbate 60, Rosmarinus officinalis (rosemary) leaf oil, lactic acid, chlorphenesin, and sorbitan isostearate, thereby completing the preparation of a skin ointment for treating labia minora skin as an ointment formulation, the skin ointment containing multi-growth factors at a concentration of 300,000 ppm on a weight basis. The prepared skin ointment was put in a 15 ml tube-shaped container.

Experimental Example 1

[0045] The prepared skin ointment for treating labia minora skin, which was contained in a 15 ml tube-shaped container, was provided to women who had undergone labia minora surgery and clitoroplasty, and while the skin ointment was periodically applied to the vulva once a day, progression after surgery was observed for two weeks.

[0046] FIG. 4 shows images showing an observed state of the degree of recovery through application of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure to patients who have undergone labia minora surgery and clitoroplasty, wherein (a) is an image before surgery, and (b) is an image after two weeks from surgery. As a result of periodically applying the skin ointment for treating labia minora skin according to the present disclosure once a day to the right side of the labia minora, which is a surgical site, it can be confirmed that a significant recovery was shown within two weeks.

Experimental Example 2

[0047] The prepared skin ointment for treating labia minora skin, which was contained in a 15 ml tube-shaped container, was provided to women who had undergone surgery for labial hypertrophy, and while the skin ointment was periodically applied to the vulva once a day, progression after surgery was observed for 20 days.

[0048] FIG. 5 shows images showing an observed state of the degree of recovery through application of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure to patients who have undergone surgery for labial hypertrophy. The image on the top of FIG. 5 is an image before surgery, and among the images on the bottom of FIG. 5, (a) is an image after 4 days from surgery, (b) is an image after one week from surgery, and (c) is an image after 19 days from surgery. In (a), (b), and (c) of FIG. 5, the left side of the labia minora shows recovery through application of a hormone-containing ointment, which is generally prescribed after labia minora surgery (represented by OINT in the images), and the right side of the labia minora shows recovery through application of the skin ointment for treating labia minora skin according to an embodiment of the present disclosure (represented by WMPF in the images). As can be seen from (a), (b), and (c) of FIG. 5, skin regeneration of a site to which the skin ointment for treating labia minora skin according to an embodiment of the present disclosure had been applied was more rapid than that of a site to which a general ointment had been applied, and recovery in terms of the shape thereof also proceeded more smoothly. As such, the skin ointment for treating labia minora skin according to an embodiment of the present disclosure has a significant effect on the treatment of wounds due to labia minora surgery, as compared to existing general ointments, and also helps to recover the shape of the labia minora, thereby improving satisfaction with labia minora surgery.

Experimental Example 3

[0049] The prepared skin ointment for treating labia minora skin, which was contained in a 15 ml tube-shaped container, was provided to women diagnosed with vulvar vestibulitis and atrophic vaginitis, and while the skin ointment was periodically applied to the vulva once a day, progression was observed for 48 days.

[0050] FIG. 6 shows images showing an observed state of the degree of recovery through application of a skin ointment for treating labia minora skin according to an embodiment of the present disclosure to patients diagnosed with vulvar vestibulitis and atrophic vaginitis. The image on the top of FIG. 6 is an image before the skin ointment for treating labia minora skin according to an embodiment of the present disclosure was applied, showing the vulva of a patient who has felt great discomfort in daily life for 10 years due to urination symptoms such as vulvar discomfort, urinary pain, frequent urination, nocturia, and urinary urgency, along with vulvar pain, dyspareunia, pelvic pain, lower abdominal pain, and back pain. The above patient was diagnosed with atrophic vaginitis and vulvar vestibulitis, and even after hormone therapy about three times, no therapeutic effect was observed. The degree of recovery of the vulva after the skin ointment for treating labia minora skin according to an embodiment of the present disclosure was periodically applied to the patient once a day was observed.

[0051] Among the images on the bottom of FIG. 6, (a) is an image after 17 days from application of the skin ointment of the present disclosure, (b) is an image after 27 days from application of the skin ointment of the present disclosure, and (c) is an image after 48 days from application of the skin ointment of the present disclosure. Specifically, as can be seen from the image on the top of FIG. 6, before the skin ointment for treating labia minora skin according to an embodiment of the present disclosure was applied, the vulva was severely swollen and showed symptoms accompanied by bleeding. In contrast, after the skin ointment for treating labia minora skin according to an embodiment of the present disclosure was periodically applied, as can be seen from (a) to (c) of FIG. 6, it can be confirmed that the bleeding of the vulva stopped and the original color of the vulva was restored. From FIG. 6, it can also be confirmed that, even in the case where no therapeutic effect is obtained through existing treatments such as hormone therapy, a significant effect of treating labia minora skin diseases such as vulvar vestibulitis can be obtained using the skin ointment for treating labia minora skin according to an embodiment of the present disclosure.

[0052] According to a skin ointment for treating labia minora skin according to the present disclosure, the skin ointment includes multi-growth factors as active ingredients, and is periodically applied to the vulva of a user so that the growth factors induce the regeneration of skin cells of the user, thereby increasing the effect of treating vulvar vestibulitis or wounds due to labia minora surgery, and addressing the fundamental causes thereof. In addition, according to the present disclosure, the skin ointment includes high concentrations of multi-growth factors and is also prepared as an ointment formulation, and thus is easily applied to the vulva of a user, and which, by excluding sex hormones, environmental hormones, steroid hormones, and antibiotic ingredients, does not break the hormonal balance of the user and can be used safely by pregnant or breast-feeding women.

[0053] The present disclosure described above can be modified or applied in various ways by those of ordinary skill in the art to which the present disclosure pertains, and the scope of the technical spirit of the present disclosure should be defined by the appended claimed.